Dual-Specificity Anti-HER-2/Neu Antisense DNA Agents for Breast Cancer Therapy.
Annual rept. 1 Jul 98-30 Jun 99
UNIVERSITY OF MEDICINE AND DENTISTRY OFNEW JERSEY PISCATAWAY
Pagination or Media Count:
The goal of the first phase of this project, which constitutes the major technological challenge to be overcome, is to design a peptide compound capable of binding to HER-2neu RNA in the presence of a large excess of unrelated RNA. To accomplish this goal, we have devised a deconvolution strategy based on synthesis of arrays of defined cationic peptides on SPOTS membranes, followed by screening with radio labeled HER-2neu RNA in the presence of a large excess of RNA. This process appears to be working satisfactorily after 3 cycles of deconvolution. This deconvolution process should be completed in the fall. Methodology for the next phase of the project, namely conjugation of a cationic peptide to an oligonucleotide and RNase H cleave assay with this conjugate has also been developed in anticipation of the final deconvoluted peptide.
- Medicine and Medical Research